Scale-up/Technology Transfer

Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News | Scale-up/Technology Transfer

CureVac, Celonic Enter COVID-19 Vax Mfg. Pact

Celonic is prepared to manufacture more than 100 million doses of CureVac’s mRNA-based COVID-19 vaccine candidate, CVnCoV, per year at Heidelberg facility.

Kristin Brooks 03.30.21

cGMP Manufacture | Drug Development | Scale-up/Technology Transfer

Fast Track Automation in Pharmaceutical Manufacturing

Drug manufacturers turn to advanced automation technologies and project execution methodologies to reduce time, cost and risk

Steve Zarichniak, Technical Solutions Consultant, Honeywell Process Solutions 03.25.21

Breaking News | Collaborations & Alliances | Industry News | Scale-up/Technology Transfer

Plus Therapeutics, Piramal Ink Master Services Agreement

Development, manufacturing and supply deal is for Plus’ Rhenium NanoLiposome intermediate drug product.

Tim Wright, Editor, Contract Pharma 03.23.21

Biologics, Proteins, Vaccines | Breaking News | Industry News | Scale-up/Technology Transfer

SpyBiotech Licenses Selexis’ SUREtechnology for HCMV Vax

Will leverage SUREtechnology Platform to generate stable, high-yield production cell lines needed for human clinical trials.

Kristin Brooks 03.18.21

cGMP Manufacture | Process Development | Scale-up/Technology Transfer

Process Intensification: Understanding the Optimal Way to Maximize Productivity

Overcoming challenges of implementation and achieving increased volume, reduced timelines, decreased footprint, lower cost of goods, and increased flexibility.

Priyanka Gupta, Head of Market Entry Strategy for Protein Based Therapeutics, Sartorius 03.09.21

Breaking News | cGMP Manufacture | Industry News | Scale-up/Technology Transfer

CureVac, Novartis Ink COVID Vax Mfg. Pact

Novartis to manufacture the mRNA and bulk drug product of the CVnCoV vaccine for up to 50 million doses by the end of 2021.

Kristin Brooks 03.04.21

Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News | Scale-up/Technology Transfer

WuXi AppTec Completes OXGENE Acquisition

Expands Cell and Gene Therapy service offerings for global customers.

Kristin Brooks 03.02.21

MaxiVAX, Minaris Enter Cell Therapy Mfg. Agreement

Minaris will provide GMP manufacturing, freezing and shipping of the MVX-ONCO-2 capsules from its site near Munich, Germany.

Kristin Brooks 02.22.21

Avid, Humanigen Enter Lenzilumab Mfg. Agreement

To expand production capacity for lenzilumab, Humanigen’s therapeutic candidate in development to treat cytokine storm associated with COVID-19.

Kristin Brooks 02.03.21

CHA Biotech Launches Global CDMO Biz

Matica Biotechnology to construct GMP facility for viral vector production in Texas.

Contract Pharma Staff 12.16.20

Sesen Bio Enters Mfg. and Supply Partnership with Qilu Pharma

Technology transfer to Qilu anticipated to be completed in mid-2021.

Contract Pharma Staff 12.09.20

Recipharm Inks Covid-19 Vax Pact with Moderna

Signs of letter of intent for aseptic fill-finish manufacturing of Moderna’s COVID-19 vaccine candidate (mRNA-1273).

Contract Pharma Staff 12.01.20

Scale-up/Technology Transfer

Ensuring Quality During the Transfer and Scale Up of Rx Drugs

Defining the key parameters and considerations for a successful technology transfer.

Tom Chang, President, Bora Pharmaceutical Laboratory Co. Ltd. 11.17.20

Scale-up/Technology Transfer

Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up

Identifying, assessing and mitigating threats at every stage of the development pipeline.

Joe Willmot, Application Leader, H.E.L Group 11.17.20

Bioanalytical Services | cGMP Manufacture | Drug Development | Scale-up/Technology Transfer

CDMOs: Keeping up with Science & Technology

Enhancing the development of increasingly advanced and complex drug candidates is needed to drive growth in the industry.

Online Exclusives Kristin Brooks, Contract Pharma 11.12.20

cGMP Manufacture | Fill/Finish | Scale-up/Technology Transfer

Ramping Up COVID-19 Vaccine Fill and Finish Capacity

As a partner to the U.S. Government, GRAM's newest facility was designed to increase large-scale fill and finish capacity with room to expand as demand grows.

Online Exclusives Kristin Brooks, Contract Pharma 11.03.20